Recent News

• 06.04.2026 - Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
• 06.04.2026 - EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
• 06.03.2026 - Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
• 06.01.2026 - UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
• 05.21.2026 - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• 05.14.2026 - Biogen Completes Acquisition of Apellis Pharmaceuticals
• 05.14.2026 - Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• 05.08.2026 - Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

Recent Filings

• 05.14.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.14.2026 - 8-K Current report
• 05.14.2026 - SC TO-T/A Tender offer statement by Third Party
• 05.14.2026 - EX-99.1 EX-99.1
• 05.12.2026 - SC TO-T/A Tender offer statement by Third Party
• 05.06.2026 - SC TO-T/A Tender offer statement by Third Party
• 05.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.29.2026 - 8-K Current report